What drugs does RIGEL PHARMS make?

RIGEL PHARMS has 3 FDA-approved drugs including TAVALISSE, GAVRETO, REZLIDHIA.

What therapeutic areas does RIGEL PHARMS focus on?

RIGEL PHARMS focuses primarily on Oncology.

← Back

Data updated: Mar 29, 2026

RIGEL PHARMS

Oncology

Pharma

RIGEL PHARMS is a pharmaceutical company focused on Oncology. Key products include TAVALISSE.

2018

Since

Drugs

Trials

Approved (2yr)

Key Drugs

TAVALISSE

fostamatinib disodium

SYK 2 indications · 2018

GAVRETO

pralsetinib

DDR1 2 indications · 2020

REZLIDHIA

olutasidenib

Oncology

IDH1 1 indications · 2022

Top Drug Revenues ProEarly access

Revenue Over Time ProEarly access

Recent Activity

SEC Filings ProEarly access

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 100%

1 drugs

Pipeline Forecast

Upcoming Trial Milestones ProEarly access

Patent Cliff ProEarly access

Competitors by Therapeutic Area

RIGEL PHARMS

Key Drugs

Top Drug Revenues ProEarly access

Revenue Over Time ProEarly access

Recent Activity

Therapeutic Areas

Pipeline Forecast

Upcoming Trial Milestones ProEarly access

Patent Cliff ProEarly access

Competitors by Therapeutic Area

All Drugs (3)

Active (3)

Discontinued (0)

Company Info

RIGEL PHARMS

Set Alert

Key Drugs

Top Drug Revenues ProEarly access

Revenue Over Time ProEarly access

Recent Activity

Therapeutic Areas

Pipeline Forecast

Upcoming Trial Milestones ProEarly access

Patent Cliff ProEarly access

Competitors by Therapeutic Area

All Drugs (3)

Active (3)

Discontinued (0)

Company Info